176 related articles for article (PubMed ID: 11677002)
1. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.
Groeneveld GJ; van Kan HJ; Toraño JS; Veldink JH; Guchelaar HJ; Wokke JH; van den Berg LH
J Neurol Sci; 2001 Oct; 191(1-2):121-5. PubMed ID: 11677002
[TBL] [Abstract][Full Text] [Related]
2. Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.
Groeneveld GJ; Van Kan HJ; Kalmijn S; Veldink JH; Guchelaar HJ; Wokke JH; Van den Berg LH
Neurology; 2003 Oct; 61(8):1141-3. PubMed ID: 14581684
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.
Bruno R; Vivier N; Montay G; Le Liboux A; Powe LK; Delumeau JC; Rhodes GR
Clin Pharmacol Ther; 1997 Nov; 62(5):518-26. PubMed ID: 9390108
[TBL] [Abstract][Full Text] [Related]
4. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
5. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.
Ajroud-Driss S; Saeed M; Khan H; Siddique N; Hung WY; Sufit R; Heller S; Armstrong J; Casey P; Siddique T; Lukas TJ
Amyotroph Lateral Scler; 2007 Oct; 8(5):305-9. PubMed ID: 17852022
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
van Kan HJ; van den Berg LH; Groeneveld GJ; van der Straaten RJ; van Vught PW; Lie-A-Huen L; Guchelaar HJ
Biopharm Drug Dispos; 2008 Apr; 29(3):139-44. PubMed ID: 18098330
[TBL] [Abstract][Full Text] [Related]
7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
8. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Dash RP; Babu RJ; Srinivas NR
Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
[TBL] [Abstract][Full Text] [Related]
9. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
Cheah BC; Vucic S; Krishnan AV; Kiernan MC
Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
[TBL] [Abstract][Full Text] [Related]
10. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
12. A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis.
van Kan HJ; Spieksma M; Groeneveld GJ; Toraño JS; van den Berg LH; Guchelaar HJ
Biomed Chromatogr; 2004 Nov; 18(9):723-6. PubMed ID: 15386583
[TBL] [Abstract][Full Text] [Related]
13. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
[TBL] [Abstract][Full Text] [Related]
14. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
van Kan HJ; Groeneveld GJ; Kalmijn S; Spieksma M; van den Berg LH; Guchelaar HJ
Br J Clin Pharmacol; 2005 Mar; 59(3):310-3. PubMed ID: 15752377
[TBL] [Abstract][Full Text] [Related]
15. Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Kwieciński H
Acta Neurol Scand; 2002 Jul; 106(1):39-43. PubMed ID: 12067327
[TBL] [Abstract][Full Text] [Related]
16. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
Dyer AM; Smith A
Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
[TBL] [Abstract][Full Text] [Related]
17. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
18. Blood oxidative stress in amyotrophic lateral sclerosis.
Bonnefont-Rousselot D; Lacomblez L; Jaudon M; Lepage S; Salachas F; Bensimon G; Bizard C; Doppler V; Delattre J; Meininger V
J Neurol Sci; 2000 Sep; 178(1):57-62. PubMed ID: 11018250
[TBL] [Abstract][Full Text] [Related]
19. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
20. Riluzole use during pregnancy in a patient with amyotrophic lateral sclerosis: a case report.
Kawamichi Y; Makino Y; Matsuda Y; Miyazaki K; Uchiyama S; Ohta H
J Int Med Res; 2010; 38(2):720-6. PubMed ID: 20515588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
